Lipid biosynthesis as a target for antibacterial agents.
about
Cloning, expression, and characterization of the human mitochondrial beta-ketoacyl synthase. Complementation of the yeast CEM1 knock-out strainDiscovery of FabH/FabF inhibitors from natural products.1,2-dithiole-3-ones as potent inhibitors of the bacterial 3-ketoacyl acyl carrier protein synthase III (FabH)Crystal structure and substrate specificity of the beta-ketoacyl-acyl carrier protein synthase III (FabH) from Staphylococcus aureusDiscovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic propertiesGenome of the opportunistic pathogen Streptococcus sanguinisThe 1.3-Angstrom-resolution crystal structure of beta-ketoacyl-acyl carrier protein synthase II from Streptococcus pneumoniaeStructure of the human beta-ketoacyl [ACP] synthase from the mitochondrial type II fatty acid synthaseCandida tropicalis expresses two mitochondrial 2-enoyl thioester reductases that are able to form both homodimers and heterodimersStructure-assisted discovery of an aminothiazole derivative as a lead molecule for inhibition of bacterial fatty-acid synthesisCrystal structure of enoyl-acyl carrier protein reductase (FabK) fromStreptococcus pneumoniaereveals the binding mode of an inhibitorIdentification and Development of Novel Inhibitors of Toxoplasma gondii Enoyl ReductaseStaphylococcus aureus FabI: Inhibition, Substrate Recognition, and Potential Implications for In Vivo EssentialityX-ray structure of a CDP-alcohol phosphatidyltransferase membrane enzyme and insights into its catalytic mechanismProtein acylation in the inhibition of insulin secretion by norepinephrine, somatostatin, galanin, and PGE2.Resistance Mechanisms and the Future of Bacterial Enoyl-Acyl Carrier Protein Reductase (FabI) AntibioticsUsing modern tools to probe the structure-function relationship of fatty acid synthasesOperon for biosynthesis of lipstatin, the Beta-lactone inhibitor of human pancreatic lipaseUse of germicides in the home and the healthcare setting: is there a relationship between germicide use and antibiotic resistance?Triclosan: current status, occurrence, environmental risks and bioaccumulation potentialInterpreting expression data with metabolic flux models: predicting Mycobacterium tuberculosis mycolic acid productionIdentification and characterization of potential therapeutic candidates in emerging human pathogen Mycobacterium abscessus: a novel hierarchical in silico approachMechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia malleiTriclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductaseRhizobium leguminosarum biovar viciae 3841, deficient in 27-hydroxyoctacosanoate-modified lipopolysaccharide, is impaired in desiccation tolerance, biofilm formation and motilityDetermination of selectivity and efficacy of fatty acid synthesis inhibitors.Computational redesign of bacterial biotin carboxylase inhibitors using structure-based virtual screening of combinatorial libraries.Integration of curated databases to identify genotype-phenotype associations.Enzymes of type II fatty acid synthesis and apicoplast differentiation and division in Eimeria tenella.Functional replacement of the FabA and FabB proteins of Escherichia coli fatty acid synthesis by Enterococcus faecalis FabZ and FabF homologues.N-O chemistry for antibiotics: discovery of N-alkyl-N-(pyridin-2-yl)hydroxylamine scaffolds as selective antibacterial agents using nitroso Diels-Alder and ene chemistry.Effect of essential oils on pathogenic bacteriaIdentification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductaseGenome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance.Roles of the active site water, histidine 303, and phenylalanine 396 in the catalytic mechanism of the elongation condensing enzyme of Streptococcus pneumoniae.Apicoplast fatty acid synthesis is essential for organelle biogenesis and parasite survival in Toxoplasma gondii.The application of computational methods to explore the diversity and structure of bacterial fatty acid synthase.How bacterial pathogens eat host lipids: implications for the development of fatty acid synthesis therapeutics.Suppression of phospholipid biosynthesis by cerulenin in the condensed Single-Protein-Production (cSPP) systemThe MUT056399 inhibitor of FabI is a new antistaphylococcal compound.
P2860
Q24338816-08644DDA-0ED9-42C3-B1B4-F3767A679F44Q24538774-57859C5D-2E60-46D7-A3DB-C93685E8C376Q24564306-57310675-4E40-4F10-830F-BFC172626FA3Q24646708-EEAB49DC-4F83-49E6-B84E-7D2AF3F85EE3Q24674719-651408C2-84FD-451B-A7B3-11B85BDBC9EEQ24680395-B46AED62-89CB-4DFC-923B-368E00F54351Q24682947-3FE7322D-52F2-476A-90F7-AA5DB25F2D14Q27641290-018EBA03-E630-4BE4-9026-E06E1AE71F68Q27641763-18C142CB-53EF-4151-BA36-E33E6FA574B4Q27649337-9DD73854-ED4C-4C4E-8D5C-FE72E2CC4413Q27649956-EA4073A2-1BD1-419B-BE5B-C72B4AE69123Q27664019-823F1CD0-B511-45B2-B247-157F1A6956DAQ27679034-9BE0E22A-0C3F-44E9-8273-B43C7353963DQ27690758-B166D3ED-1A72-4A37-B481-5FA8E4E83C53Q27863764-658FE7E0-C877-4902-9677-A6C032E98692Q28069943-F228A613-1898-4933-939F-1D3C306B8B1EQ28080940-CFF853E5-A0C7-4658-AD4F-74C4F8576142Q28248341-284D7A64-BBF6-4E0A-9E91-7570389B0118Q28265803-3567D812-B8A0-4C94-BC92-9C0EC84478B6Q28395589-F454DB3B-64B1-4B7A-BB63-159B1C811DC0Q28475985-811323BF-2F91-4E53-99C4-60E849064059Q28488335-179FF7C5-3C6E-44DA-9189-5118F4AE4DC3Q28492113-925D2A71-04F9-4933-B471-D189E0755CF7Q28492833-B8701D9F-3BFA-4DE4-AE03-DB8364DED7F6Q30482187-EFF14BA5-A884-49F0-BBB2-9B79F47724F2Q31123125-D2C3D965-F346-4251-80EE-F4AC1FAB02C6Q31155333-47775144-3129-4060-B799-8086250BF879Q33260275-BA5C5DEF-77AB-49F7-9971-0FF90818F0E2Q33579443-7D01F25C-572E-491C-880C-5B47D3C52AF6Q33979089-F7CE24BA-C78A-4D8D-8B92-6BD754EAD013Q34000399-D19BB80C-A515-4E4C-BF13-E49F8B9EF4A8Q34039158-B1C0C2BB-1AE7-433B-92F2-B6E82D022951Q34315832-0798BEEA-85F2-4368-8EE6-85E61B12140FQ34367960-66DCC26C-2446-4A59-AB9A-D2672E55429EQ34514386-DFB2ECED-B6A0-4BDC-B20C-2B3B99500486Q35016560-D7664B72-A0F8-425F-8E91-D7420BE942DCQ35041188-5DC6C08A-189C-4FDD-BD88-71B09BDC88DEQ35172866-55523908-E81B-4430-BEB4-1B003F3B67D5Q35189863-7E753B37-BE33-42E0-B765-21986C0AAFBCQ35270339-8208E71B-10D7-4BF1-B133-698FEBAA415C
P2860
Lipid biosynthesis as a target for antibacterial agents.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Lipid biosynthesis as a target for antibacterial agents.
@ast
Lipid biosynthesis as a target for antibacterial agents.
@en
Lipid biosynthesis as a target for antibacterial agents.
@nl
type
label
Lipid biosynthesis as a target for antibacterial agents.
@ast
Lipid biosynthesis as a target for antibacterial agents.
@en
Lipid biosynthesis as a target for antibacterial agents.
@nl
prefLabel
Lipid biosynthesis as a target for antibacterial agents.
@ast
Lipid biosynthesis as a target for antibacterial agents.
@en
Lipid biosynthesis as a target for antibacterial agents.
@nl
P2093
P1476
Lipid biosynthesis as a target for antibacterial agents.
@en
P2093
P304
P356
10.1016/S0163-7827(01)00012-1
P577
2001-11-01T00:00:00Z